Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | FLT1 | P17948 | 4/20 | 0.39 |
| ▸ | KDR | P35968 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17438056 | 0.86 | FLT1 (0.43) | F2PLAUKLKB1ELANEL3MBTL1 | |
| SCHEMBL31094770 | 0.85 | HDAC4 (0.42) | RAB9ANPC1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL25660343 | 0.81 | KMT2A (0.42) | L3MBTL1FLT1KDRRAB9ANPC1 | |
| SCHEMBL7056151 | 0.80 | F2 (0.48) | F2PLAUKLKB1ELANEL3MBTL1 | |
| SCHEMBL2214930 | 0.80 | MAPK1 (0.38) | L3MBTL1FLT1KDRRAB9ANPC1 | |
| SCHEMBL24937400 | 0.80 | L3MBTL1 (0.56) | F2PLAUKLKB1ELANEL3MBTL1 | |
| SCHEMBL7056155 | 0.80 | F2 (0.48) | F2PLAUKLKB1ELANEL3MBTL1 | |
| SCHEMBL25564436 | 0.79 | MAPK1 (0.35) | L3MBTL1FLT1KDRRAB9ANPC1 | |
| SCHEMBL31460083 | 0.79 | F2 (0.47) | F2PLAUKLKB1ELANEL3MBTL1 | |
| SCHEMBL17076689 | 0.79 | CCNC (0.39) | FLT1KDRRAB9ANPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919908-B2 | Thienopyrimidinone derivative and application thereof in preparing anticancer drug | HENAN GENUINE BIOTECH CO., LTD. (CN) | 2021-02-16 | — | — | US | disclosed |
| EP-3567043-A1 | THIENOPYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MANUFACTURING OF ANTITUMOR DRUGS | Henan Genuine Biotech Co., Ltd. (CN) | 2019-11-13 | — | — | EP | disclosed |
| US-20190330230-A1 | THIENOPYRIMIDINONE DERIVATIVE AND APPLICATION THEREOF IN PREPARING ANTICANCER DRUG | HENAN GENUINE BIOTECH CO., LTD. (CN) | 2019-10-31 | — | — | US | disclosed |
| EP-2616465-B1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2015-11-04 | — | — | EP | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | F2 1610/4885PLAU 4448/4885KLKB1 4609/4885 |
| US-10919908-B2 | Thienopyrimidinone derivative and application thereof in preparing anticancer drug | CCND3, CCND1, CCND2 | F2 352/4885PLAU 4354/4885KLKB1 4233/4885 |
| US-20190330230-A1 | THIENOPYRIMIDINONE DERIVATIVE AND APPLICATION THEREOF IN PREPARING ANTICANCER DRUG | CCND3, CCND1, CCND2 | F2 352/4885PLAU 4354/4885KLKB1 4233/4885 |
| US-20140051676-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | F2 1610/4885PLAU 4448/4885KLKB1 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.